Kelly H. Zou

Dr. Kelly H. Zou, Ph.D., PStat, FASA is CEO, AI4Purpose and Advisory, as well as Anthropic's Claude Ambassador in both Healthcare and FinTech in New York City. As an Expert in Residence, she serves as an advisor to ARPA-H. Dr. Zou also serves as President, American Statistical Association (ASA)'s New York City Chapter, and Executive Committee Member, and Chair, Caucus of Industry Representatives, ASA, Digital Health and Technologies Interest Group's Advisory Committee, Membership Council, and AI Expert Group Member, AcademyHealth. She is an elected ASA Fellow and an Accredited Professional Statistician.

Previously at Pfizer Inc, she was Vice President and Head of Medical Analytics & Insights; Senior Director of Real World Evidence, Group Lead of Methods & Algorithms and Analytic Science Lead; Senior Director of Statistics. She was also Head, Global Medical Analytics, Real-World Evidence, and Health Economics and Outcomes Research at Viatris Inc. (merged from Pfizer). Earlier, she was Associate Professor of Radiology at Harvard Medical School, as well as Director of Biostatistics at its affiliated teaching hospitals. She was also Associate Director of Rates at Barclays Capital.

She received both MA and PhD degrees in Statistics from the University of Rochester. She completed her Postdoctoral Fellowship at Harvard. Her research interests include health policy, real world evidence, signal detection, and artificial intelligence, with well-over 150 professional articles and 5 books, including a Reuters prize. She was featured as an Outstanding Woman in Data Analytics by Forbes, an Inspirational Women in Statistics & Data Science by Wiley, and an Accomplished Woman in Statistics and Data Science by the American Statistical Association. She was the winner of the Chief Data and Analytics Officers’ Forum’s Future Thinking Award, AI100, Top 50 Data & Analytics Team Award, Top 100 Individual Award, Reuters Events Pharma USA’s Most Valuable Data & Insights Initiative Team Award, and Global Recognition Award. She was a Reuters Trailblazer. She is an editorial board member and judge for Significance, UK Royal Statistical Society, ASA, and Statistical Society of Australia.

‍